Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

1 antibody neutralizes all 3 pathogenic human coronaviruses

1 antibody neutralizes all 3 pathogenic human coronaviruses

A groundbreaking therapeutic antibody has been developed by researchers that effectively neutralizes all three highly pathogenic human coronaviruses – SARS-CoV, SARS-CoV-2, and MERS-CoV. This significant discovery comes amidst ongoing infections and potential new outbreaks of these viruses. Led by the Institute for Biomedical Sciences at Georgia State University, the study involved researchers from multiple American institutions.

Nanobodies, tiny antibody fragments, were identified and selected for their strong binding affinity and cost-effective production. These nanobodies, specifically 3B11 against SARS-CoV and SARS-CoV-2, and 1C11 against MERS-CoV, bound to the receptor-binding domains (RBDs) of these viruses. The RBDs are crucial parts of the viral spike proteins that facilitate cell entry.

Nanobody 3B11 neutralized diverse SARS-CoV and SARS-CoV-2 strains, while 1C11 effectively neutralized all tested MERS-CoV strains. When combined with the Fc segment of a human antibody, the potency of 1C11 significantly increased. These nanobodies work by obstructing the interaction between viral RBDs and their corresponding human cell receptors.

Investigations using cryo-electron microscopy, computational modeling, and epitope-mapping revealed the unique sites on the viral proteins recognized by the nanobodies, providing insights into their mechanism of action. A bispecific nanobody, 3B11−1C11-Fc, was created to target all three RBDs simultaneously. This bispecific nanobody remained stable under various pH and temperature conditions, and could be produced in large quantities at high yield in mammalian cells, ensuring potential scalability for widespread use.

In mouse models, a single dose of this bispecific nanobody significantly decreased viral loads and protected the animals from infections caused by SARS-CoV, SARS-CoV-2, and MERS-CoV, without causing severe side effects. The lead researcher, Distinguished University Professor Lanying Du, expressed optimism about this bispecific nanobody's potential for further therapeutic development, highlighting its promise in combating these highly pathogenic coronaviruses.

The study, funded by the National Institute of Allergy and Infectious Diseases and the National Institute of General Medical Sciences of the National Institutes of Health, was published in the journal ACS Nano.

Written by urgent.news from Futurity's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

Read the original at futurity.org →

More in Health & Medicine

Alzheimer’s Breakthrough Targets Genes That May Raise Risk up to 12 Times

Could an effective gene therapy for Alzheimer's be on the horizon? Dr. Kevin Kemp told Newsweek that he thinks so.

  • University of Bristol scientists develop gene therapy targeting APOE4 gene.
  • Therapy converts APOE4 to APOE3, reducing Alzheimer's risk up to 12 times.
  • Research led by Dr. Kevin Kemp shows promising results in human immune cells.

More from Friday 20 November →